CTLA4 and cancer: The two most potent examples of T cell immune checkpoint molecules, anti-CTLA-4 and anti-programmed cell death protein 1 (PD-1) antibodies, provide a synergistic effect to regulate antitumoral immunity in a complementary manner that has revolutionized cancer treatment [59,60].